BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

55.75 UNCHANGED

Delayed Quote Updated: 12:04 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Opportunity with Strong Fundamentals and Accelerating Growth ↗

May 19, 2026

Via Chartmill

2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down

May 14, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Via StockStory

Topics Credit Cards

BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 11, 2026

BioMarin’s first quarter saw revenue growth driven by continued demand for its enzyme therapies and Voxzogo, but the company missed Wall Street’s revenue and...

Via StockStory

Topics Earnings

BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook

May 05, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio...

Via StockStory

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance ↗

May 04, 2026

Via Chartmill

Topics Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a Compelling Value Stock ↗

April 17, 2026

Via Chartmill

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

March 16, 2026

Via Chartmill

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss ↗

February 23, 2026

Via Chartmill

BioMarin (BMRN) Q1 2026 Earnings Transcript ↗

May 04, 2026

BioMarin (BMRN) Q1 2026 Earnings Transcript

Via The Motley Fool

BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates

May 04, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio...

Via StockStory

BioMarin (BMRN) Q4 2025 Earnings Transcript ↗

May 04, 2026

BioMarin (BMRN) Q4 2025 Earnings Transcript

Via The Motley Fool

BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect

May 02, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday afternoon. Here’s what to look for. BioMarin Pharmaceutical beat ...

Via StockStory

Topics Artificial Intelligence

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

2 Profitable Stocks with Promising Prospects and 1 Facing Challenges

April 08, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

1 of Wall Street’s Favorite Stock with Promising Prospects and 2 We Find Risky

March 26, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

March 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...

Via StockStory

Topics Artificial Intelligence

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

Via The Motley Fool

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

March 12, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

2 Reasons to Like BMRN (and 1 Not So Much)

March 02, 2026

BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%. Does th...

Via StockStory

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

February 23, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 17% year on year to $874.6 million. The company expects the...

Via StockStory

Topics Earnings

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

February 21, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.